Servier acquires Pixuvri from CTI BioPharma
The treatment was approved for use in the European Union in June this year.
3rd October 2019
Latest news
PIPA releases patient enquiries guidance
The guidance was formed after PIPA found that information provided in response to patient enquiries varied significantly between companies.
3rd October 2019
ABPI details Brexit plans at PIPA conference
ABPI Brexit preparations include ensuring continued UK participation in EU regulatory and medicines safety processes.
3rd October 2019
Gov't moves to curb HRT shortages
Plans will support existing efforts to reduce medicine shortages to protect NHS patients.
3rd October 2019
NICE draft 'no' for Roche's Tecentriq
The committee felt that comparison to existing treatments for the condition was "unreliable and lacked validity".
3rd October 2019
2018 winner offers insight into the Medical & Scientific Excellence Awards
Deborah Clarke of Boehringer Ingelheim reveals her experience with the competition and the important role it plays within the industry.
3rd October 2019
Novartis, Microsoft collab to ‘transform medicine’ with AI
The companies have committed to a multi-year research and development effort which will focus on AI empowerment and AI exploration.
2nd October 2019
Tickets available for the 2019 Sales Awards gala dinner and ceremony
This year’s awards ceremony will be taking place at the Chelsea Harbour Hotel on the 14th November.
2nd October 2019
Tecentriq combo proves effective in bladder cancer
The drug improved progression-free survival to 8.2 months from 6.3 months.
2nd October 2019
Zejula successful in advanced ovarian cancer
GlaxoSmithKline presented the results at the ESMO Congress.
2nd October 2019
Novartis announces positive asthma results
Marketing applications for the treatments are currently being reviewed by the EMA.
2nd October 2019
Survey reveals women with cancer feel ‘stigmatised’
The report found that there is still significant “room for improvement to promote understanding of all cancers and their risk factors."
1st October 2019
Continued success for Lynparza in ovarian cancer
The drug improved progression-free survival time to a median of 22.1 months, compared to 16.6 months.
1st October 2019
Lynparza bags positive prostate cancer results
The drug more than doubled median radiographic progression-free survival.
1st October 2019
Invokana bags FDA approval
The treatment has been approved to reduce the risk of hospitalisation for heart failure in certain patients with type II diabetes.
1st October 2019
